SwastiChemEx: Generic Celebrex patent litigation with Pfizer

Wednesday, 4 June 2014

Generic Celebrex patent litigation with Pfizer

Under the terms of the agreement, Mylan will begin selling product at the earliest market formation, however in any case not later than December 2014. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission.

No comments:

Post a Comment